Garden State Investment Advisory Services LLC Sells 130 Shares of Novo Nordisk A/S (NYSE:NVO)

Garden State Investment Advisory Services LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 5.7% during the third quarter, HoldingsChannel reports. The firm owned 2,143 shares of the company’s stock after selling 130 shares during the quarter. Garden State Investment Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $255,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. American Trust raised its position in Novo Nordisk A/S by 139.1% during the third quarter. American Trust now owns 12,725 shares of the company’s stock worth $1,515,000 after acquiring an additional 7,402 shares in the last quarter. Tri Ri Asset Management Corp bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $17,276,000. Peapack Gladstone Financial Corp increased its stake in shares of Novo Nordisk A/S by 17.2% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 28,156 shares of the company’s stock worth $3,353,000 after purchasing an additional 4,122 shares during the last quarter. Synovus Financial Corp raised its holdings in shares of Novo Nordisk A/S by 5.2% in the 3rd quarter. Synovus Financial Corp now owns 54,697 shares of the company’s stock valued at $6,513,000 after purchasing an additional 2,684 shares during the period. Finally, Optimist Retirement Group LLC lifted its stake in Novo Nordisk A/S by 4.3% in the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after purchasing an additional 112 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $106.96 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $479.99 billion, a price-to-earnings ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40. The stock’s fifty day moving average price is $110.59 and its two-hundred day moving average price is $126.27. Novo Nordisk A/S has a one year low of $96.53 and a one year high of $148.15.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $150.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.